957135-12-5

Basic information

• Product Name: (5S,8S,10aR)-Methyl 5-(tert-butoxycarbonylaMino)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxylate
• Synonyms: (5S,8S,10aR)-Methyl 5-(tert-butoxycarbonylaMino)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxylate;Pyrrolo[1,2-a][1,5]diazocine-8-carboxylic acid, 5-[[(1,1-diMethylethoxy)carbonyl]aMino]decahydro-6-oxo-, Methyl ester, (5S,8S,10aR)-;UKRIZEJDRITPFH-WOPDTQHZSA-N
• CAS NO: 957135-12-5
• Molecular Formula: C16H27N3O5
• Molecular Weight: 341.40268
• Mol File: 957135-12-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (5S,8S,10aR)-Methyl 5-(tert-butoxycarbonylaMino)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (5S,8S,10aR)-Methyl 5-(tert-butoxycarbonylaMino)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxylate(957135-12-5)
• EPA Substance Registry System: (5S,8S,10aR)-Methyl 5-(tert-butoxycarbonylaMino)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxylate(957135-12-5)

Safety Data

• Hazardous Substances Data: 957135-12-5(Hazardous Substances Data)

Usage

General Description

The chemical compound "(5S,8S,10aR)-methyl 5-(tert-butoxycarbonylamino)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxylate" is a complex molecule with a long and specific structure. It consists of a 5-membered nitrogen-containing ring and a 6-membered nitrogen-containing ring fused together, with additional carbon and oxygen atoms attached. The compound also contains a methyl group, a tert-butoxycarbonylamino group, and a carboxylate group. (5S,8S,10aR)-methyl 5-(tert-butoxycarbonylamino)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxylate likely has potential applications in medicinal chemistry and drug development due to its unique structure and functional groups, but further research and analysis would be needed to fully understand its properties and potential uses.

Upstream product

• 195964-54-6 1-tert-butyl 2-methyl (2S)-5-methoxypyrrolidine-1,2-dicarboxylate 
• 637355-27-2 5-allyloxy-pyrrolidine-2-carboxylic acid methyl ester hydrochloride 
• 98-79-3 L-Pyroglutamic acid 
• 188200-05-7 1-(tertbutyloxycarbonyl)-5-(hydroxy)pyrrolidine-2-carboxylic acid methyl ester 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 4931-66-2 methyl (S)-pyroglutamate 
• 65710-57-8 3-{[(benzyloxy)carbonyl]amino}-N-(tert-butoxycarbonyl)-L-alanine 
• 1296138-83-4 YP-367 
• 1296138-82-3 YP-348 
• 65710-58-9 N^α-Boc,N^β-Z-Dap*DCHA 
• 195964-65-9 (2S)-5-allyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 1071993-04-8 C₁₆H₂₅N₃O₅ 
• 957135-10-3 C₂₄H₃₃N₃O₈ 

Relevant articles and documents

Debio-1143: Inhibitor of apoptosis protein (IAP) antagonist Cancer therapy

Inhibitors of apoptosis proteins (IAPs) block caspases, modulate nuclear factor NF-êB signaling pathways and are involved in resistance to cancer therapies. Debio-1143, a mimetic of an endogenous IAP inhibitor (second mitochondriaderived activator of caspases [SMAC]), may help to overcome treatment resistance and has demonstrated antitumor activity in various cancer cell lines and xenograft models, alone or in combination with chemotherapy, radiotherapy or immunotherapies. So far, about 150 cancer patients have been enrolled in 5 registered early-phase clinical trials testing Debio-1143. Tolerability was acceptable even when the drug was used in combination therapies. In monotherapy, pharmacokinetics was linear, but varied considerably among patients in combination settings. High tumor penetration and on-target activity were consistently shown in patient surrogate tissues and tumor biopsies. Tumor responses to second-(or higher) line monotherapy in patients with various advanced cancers were rather weak, but currently followed approaches as an adjunct to existing cancer therapies look encouraging. Still, to identify ideal target populations and concomitant regimens remains challenging.

DIAZO BICYCLIC SMAC MIMETICS AND THE USES THEREOF

The invention relates to diazo bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

BIVALENT SMAC MIMETICS AND THE USES THEREOF

The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosi